In this trial, the patients were randomized to either weekly nab-paclitaxel or solvent-based paclitaxel for 12 weeks followed by standard epirubicin/cyclophosphamide; patients with HER2-positive breast cancers received trastuzumab and pertuzumab every three weeks, simultaneously to all chemotherapy cycles [57]. Here, ERBB2 is linked to breast cancer.